Trademark Search in Canada

BYVASDA

View On IC.GC.CA

REGISTERED

on 31 May 2023

Last Applicant/ Owned by

INNOVENT BIOLOGICS (SUZHOU) CO. LTD.

No. 168, Dongping Street, Suzhou Industrial Park,Suzhou CityJiangsu Province

Serial Number

2066907 filed on 23^rd Sept 2020

Registration Number

TMA1182475 registered on 31^st May 2023

Registration expiry Date

23^rd Sept 2030

Correspondent Address

NEOMARK LTD.

7450 rue Saint-HubertMontréal

QUEBEC

H2R2N3

BYVASDA

Trademark usage description

medicines for human purposes for the treatment of tumors, ophthalmology diseases, cardiovascular diseases, autoimmune diseases and disorders, immunolo Read More

Vienna Information

5 . 5 . 18

Umbellate flowersFleurs disposées en ombelles

5 . 5 . 20

Stylized flowersFleurs stylisées

5 . 5 . 21

One flowerUne fleur

Classification Information

Class [005]
Medicines for human purposes for the treatment of tumors, ophthalmology diseases, cardiovascular diseases, autoimmune diseases and disorders, immunologic deficiency syndromes, anemia, anorexia, arthritis, bulimia nervosa, gout, hyperlipidemia, hypothyroidism, insulin resistance, metabolic syndrome, muscular dystrophy, obesity, osteoarthritis, blood disorders, diabetes, growth and thyroid disorders, primary periodic paralysis, glucagonoma, disorders relating to sexual reproduction and fertility, respiratory system diseases, central nervous system [CNS] diseases, cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies, plexopathies, genetic diseases; medicines for human purposes that modulate the immune system; medicines for human purposes for regulating the immune system; medicines for human purposes being antivirals; biochemical medicines for the treatment of cancer; liquid medicines for the treatment of tumors, ophthalmology diseases, cardiovascular diseases, autoimmune diseases and disorders, immunologic deficiency syndromes, anemia, anorexia, arthritis, bulimia nervosa, gout, hyperlipidemia, hypothyroidism, insulin resistance, metabolic syndrome, muscular dystrophy, obesity, osteoarthritis, blood disorders, diabetes, growth and thyroid disorders, primary periodic paralysis, glucagonoma, disorders relating to sexual reproduction and fertility, respiratory system diseases, central nervous system [CNS] diseases, cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies, plexopathies, genetic diseases; liquid medicines for human purposes that modulate the immune system; liquid medicines for human purposes for regulating the immune system; liquid medicines for human purposes being antivirals; blood substitutes; pharmaceutical preparations for the treatment of gastrointestinal disorders; diagnostic chemical reagents for medical purposes; biological preparations for medical purposes for the treatment of osteoporosis; biological tissue cultures for medical purposes; drugs for medical purposes for the treatment of fever; diagnostic preparations for medical laboratory use; vaccines, namely human vaccines, veterinary vaccines; injectable medicine for treating tuberculosis

Classification kind code

Mark Details

Serial Number

2066907

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 48 on 13^th Sept 2022	Agent Changed
Submitted for opposition 22 on 16^th Mar 2022	Search Recorded
Submitted for opposition 20 on 16^th Mar 2022	Examiner's First Report
Submitted for opposition 223 on 16^th Mar 2022	Total Provisional Refusal
Submitted for opposition 256 on 27^th Sept 2021	Notification of Possible Opposition Sent
Submitted for opposition 31 on 30^th Nov 2020	Formalized
Submitted for opposition 1 on 30^th Nov 2020	Created
Submitted for opposition 257 on 26^th Nov 2020	Designation Notification - Madrid Protocol
Submitted for opposition 228 on 23^rd Sept 2020	International Registration
Submitted for opposition 30 on 23^rd Sept 2020	Filed